In year three of the French revolution, a law was enacted to realize the rallying cry, “un roi, une loi, un poids, et une mesure” (One king, one law, one weight, and one measure) and this became the introduction of the metric system. The one… Read More »The Importance Of What Is Difficult To Measure: How NeoVentures’ Aptamarker Platform Is Setting New Standards in Protein Measurement

Aptamarker Paradigm Shift: NeoVentures Biotechnology’s Aptamarker platform challenges the traditional approach to biomarker discovery by eliminating the need to first understand the cause of a disease. Revolutionizing Healthcare: Aptamarker enables the identification of disease biomarkers without the constraints of unraveling disease causation, leading to faster… Read More »Revolutionizing Disease Detection: NeoVentures Biotechnology’s Aptamarker Platform

Cancer is a formidable adversary that continues to challenge the field of medicine. Despite significant advancements in cancer research and treatment, finding precise and effective methods for diagnosing and treating cancer remains a top priority. One promising avenue of research that has gained momentum in… Read More »Targeted Hope: Aptamers in the Fight Against Cancer

Aptamers are synthetic, single-stranded DNA, RNA, or peptide molecules with high specificity and affinity for a wide range of target molecules, making them valuable in diagnostics. Advantages of aptamers in diagnostics include high specificity, versatility for various target types, and stability under different environmental conditions.… Read More »Aptamers: Revolutionizing Diagnostics in the Next Generation

NeoVentures is pleased to announce that a long term project with a Fortune 500 company regarding the development of an aptamer that binds to a transmembrane receptor is currently under review by the FDA. This multi-year project was contracted to NeoVentures because of our expertise… Read More »Aptamers That Bind to a Transmembrane Receptor

I was just in Leipzig for the in-person portion of BIO-Europe 2022 that ran from October 24th to 26th. It is great to be back in person at BIO-Europe, the last event I was able to attend was in Hamburg in 2019. There were more… Read More »BIO-Europe 2022

At NeoVentures we are global leaders in the development and application of chemistries that enable aptamer performance in diagnostic devices. Usually I start my blogs with a cultural analogy, sorry to disappoint with the adapter image this time. The reason for the analogy is to… Read More »Aptamer Chemistry Series II : The Adapter

Think about listening to great jazz, late at night in a quiet club. The saxophone riffs off a melody laid down by the trumpet and vice-versa back and forth. The complexity of the interacting sounds takes us away from the expected melody in eddies drifting… Read More »FRELEX : Enabling diagnosis of complexes.

When we look at the night’s sky and see the moon, we could describe their relationship as a fixed binding event. In fact, this is a dynamic system where the earth, the moon and the sun play a role. The same as the earth and… Read More »Signal versus Noise IV: Binding affinity

Mariners knew that there were dangers in uncharted waters and those that wandered there may not come back. It is safe to work with aptamers in controlled buffers and many papers have been published detailing how well they work close to the shore where maps… Read More »Signal Versus Noise II

Signal versus noise is not only the core basis of the development of diagnostic devices but the core basis of all scientific questions. This may be the core question of our individual existence as a brief scream against the silence of the universe, but that… Read More »Signal versus noise

At NeoVentures we are the global leaders in the identification of aptamers against viruses. We have developed aptamers against HIV, HCV, HSV, rhinovirus, and SARS-CoV-2 for a broad range of applications from neutralization of infection to diagnosis. Why aptamers for these applications? For neutralization of… Read More »Aptamers for virus infection , prevention and diagnosis

Why consider aptamers for therapeutic applications? There has only been one aptamer based therapeutic ever approved, Macugen (https://en.wikipedia.org/wiki/Pegaptanib) and the commercial sales for this treatment were not blockbuster… The biggest issue facing any therapeutic development effort is definitely the risk of failure, especially the risk… Read More »Why Consider Aptamers for therapeutic Applications ?

We have succeeded in developing high affinity and high specificity aptamers for both the spike protein (S1) and the nucleoprotein from SARS-CoV-2 (COVID-19). These aptamers have been characterized and are available for purchase. We are working with several partners globally to apply these aptamers in… Read More »NeoVentures Develops Aptamers for COVID-19

NeoVentures has successfully developed aptamers for both the spike protein and the nucleoprotein of SARS-CoV-2 (COVID-19). Spike protein aptamers were developed against a recombinant S1 protein from the Wuhan strain expressed in HEK293 cells in order to maintain appropriate glycosylation, counter selection was performed against… Read More »Neo Ventures Announcement

In a previous blog I stressed the need to further improve aptamer performance after SELEX identification in order to develop aptamers that are effective enough to be commercialized. I promised that I would describe how we do this at NeoVentures in more detail in a… Read More »Optimized Aptamers II